Clarius Group LLC Has $835,000 Stock Holdings in Stryker Corporation $SYK

Clarius Group LLC grew its holdings in Stryker Corporation (NYSE:SYK) by 4.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,111 shares of the medical technology company’s stock after buying an additional 84 shares during the quarter. Clarius Group LLC’s holdings in Stryker were worth $835,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Goodman Advisory Group LLC bought a new stake in shares of Stryker in the 1st quarter worth about $32,000. City Holding Co. grew its holdings in shares of Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 74 shares during the last quarter. Ridgewood Investments LLC grew its holdings in shares of Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd bought a new stake in shares of Stryker in the 1st quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Stryker in the 1st quarter worth about $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SYK shares. Wells Fargo & Company upped their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Redburn Partners set a $420.00 price objective on shares of Stryker in a report on Thursday, September 18th. Needham & Company LLC increased their price objective on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a report on Saturday, September 27th. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $430.33.

Stryker Stock Up 1.1%

Shares of NYSE:SYK opened at $370.59 on Monday. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a 50 day moving average of $382.81 and a 200-day moving average of $378.96. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a market cap of $141.68 billion, a price-to-earnings ratio of 49.08, a P/E/G ratio of 2.67 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter in the previous year, the company earned $2.81 EPS. Stryker’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, sell-side analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.